ENTERIC AND FOAM-FORMING RABEPRAZOLE TABLETS

              Helicobacter pylori (H. pylori) is considered the main cause of gastroduodenal diseases. For eradication Helicobacter, triple therapy actively used, so-called "Gold standard", which combines antibiotics and proton pump inhibitors. Among innovative delivery systems for gastroenterological drug formulationsfoams appear to be particular interest.Foams are light systems. Unlike solid medicationforms, theyare not simply depositedin gastrointestinal mucosa, on contrary, they grow in volume,have a large contact surface, completely cover mucous membrane, penetrate it. Targeted delivery, enteric-soluble foam-forming tablets have been developed from standard"ingredients with significant amount antacids. The study aimed determine composition enteric-coated rabeprazole sodium process  their  technology. Based biopharmaceutical research, optimal powder has beenformulated as an auxiliary substance preparation tablets, following composition: lauryl sulfate, lecithin, METHOCEL™ E6 PLV (0.75:1.25:5) 7%, Xanthan, guar gum ratio  1:1 - 2%, Isomalt 10%. studies, formulations core,tabletcoating composition, manufacturing technologyof rabeprazolehave beendrawn up. physical, chemical, technological properties studied. And, we ascertainedthat technology appliedfor their meets quality requirements this medication: its appearance, dosing accuracy, mechanical strength, solubility, foaming, stability, etc. dissolution profile generated at pH 1.2 6.8,has We Active Pharmaceutical Ingredient (API)is almost 100% resistant acidic environment: API released during 2 hours acid area insignificant varies within 3%. tablet 30 min 6.